The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
|ClinicalTrials.gov Identifier: NCT01227213|
Recruitment Status : Completed
First Posted : October 25, 2010
Last Update Posted : October 30, 2015
Rationale: The introduction of angiogenesis inhibitors, like sunitinib and bevacizumab, has improved the outcome of patients with several types of cancer remarkably. However, their application is hampered by side effects, such as development of hypertension with consequences for renal and cardiac function. Moreover patients treated with angiogenesis inhibitors may suffer from weight loss, and insulin sensitivity during treatment appears to change. The treatment with angiogenesis inhibitors, will improve life expectancy of patients with various cancer diagnoses and therefore the clinical relevance of both short term and long lasting adverse events will translate into reduced quality of life. In addition, premature withdrawal of angiogenesis inhibitors due to side effects may result in lower response, shorter duration of response and possibly a shorter survival. Therefore, adequate treatment of above mentioned side effects in patients treated with angiogenesis inhibitors is of relevance for the response rate, the duration of progression free survival and overall survival and for quality of life.
Mechanistic insight in the pathogenesis of these side effects will help optimizing treatment.
Objective: The primary objective of the study is to investigate the effect of sunitinib on endothelial function, insulin sensitivity, renal function and renal blood flow.
Study design: Single-centre non randomized observational study Study population: 30 Patients (>18 years old) starting with sunitinib as treatment for metastatic renal cell carcinoma.
|Condition or disease|
|Hypertension Renal Function Insulin Sensitivity Renal Cell Carcinoma|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||November 2013|
- Endothelial function [ Time Frame: 2 weeks ]
Vasomotor response to intra-arterially administered doses of acetylcholine and nitroprusside before and after start sunitinib
- Insulin sensitivity [ Time Frame: 2 weeks ]
Insulin sensitivity measured by hyperinsulinemic euglycemic clamp before and after start sunitinib
- GFR and renal perfusion flow [ Time Frame: 2 weeks ]
GFR and RPF measured by PAH and inulin clearance before and after start of treatment with sunitinib
- Blood pressure [ Time Frame: 3 months ]
- Weight [ Time Frame: 3 months ]
- Laboratory evaluations [ Time Frame: 12 weeks ]
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01227213
|Radboud University Nijmegen Medical Centre|
|Nijmegen, Netherlands, 6500HB|